Arvinas (ARVN) closed at $6.46 on November 20, 2026, down 4.2% from the previous close, on volume of 1,044,217 shares (30-day average 867,031).
Data as of November 20, 2026.
GeneDx Announces Leadership Transition
Business Wire (Wed, 18-Nov 8:00 AM ET)
Arvinas Updates First-in-Human ARV-806 Study in KRAS G12D Cancers
TipRanks (Tue, 17-Nov 11:30 AM ET)
Arvinas to Present at Jefferies Global Healthcare Conference
Globe Newswire (Wed, 11-Nov 7:00 AM ET)
Globe Newswire (Wed, 4-Nov 4:01 PM ET)
Arvinas Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Globe Newswire (Tue, 3-Nov 7:00 AM ET)
Globe Newswire (Tue, 27-Oct 4:01 PM ET)
Arvinas to Report Third Quarter 2026 Financial Results on November 3, 2026
Globe Newswire (Tue, 27-Oct 7:00 AM ET)
Globe Newswire (Wed, 7-Oct 7:00 AM ET)
Globe Newswire (Thu, 1-Oct 4:01 PM ET)
Arvinas Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Globe Newswire (Tue, 29-Sep 4:01 PM ET)
Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.
Arvinas trades on the NASDAQ stock market under the symbol ARVN.
As of November 20, 2026, ARVN stock price declined to $6.46 with 1,044,217 million shares trading.
ARVN has a beta of 1.94, meaning it tends to be more sensitive to market movements. ARVN has a correlation of 0.23 to the broad based SPY ETF.
ARVN has a market cap of $422.39 million. This is considered a Small Cap stock.
Last quarter Arvinas reported $500,000 in Revenue and -$.82 earnings per share. This fell short of revenue expectation by $-18 million and exceeded earnings estimates by $.10.
In the last 3 years, ARVN traded as high as $53.08 and as low as $5.90.
The top ETF exchange traded funds that ARVN belongs to (by Net Assets): VTI, IWM, VXF, XPH, FESM.
ARVN has underperformed the market in the last year with a return of -44.0%, while the SPY ETF gained +5.2%. In the last 3 month period, ARVN fell short of the market, returning -33.3%, while SPY returned -10.1%. However, in the most recent 2 weeks ARVN has outperformed the stock market by returning -1.4%, while SPY returned -5.9%.
ARVN support price is $6.48 and resistance is $7.01 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ARVN shares will trade within this expected range on the day.